IFPMA Welcomes Set-Up of New African Medicines Agency
Geneva, 25 May 2018 – To mark Africa Day, soon after African health ministers of 55-country African Union, all gathered at the 71st World Health Assembly, unanimously adopted a treaty to establish the African Medicines Agency, IFPMA seizes this momentum to welcome this important milestone. The new African Medicines Agency (AMA) will support the varying regulatory capacities of its member states and will help set-up a comprehensive, regional system of regulatory supervision that serves to harmonize regulations across national boundaries, make efficient use of its limited resources, and deepen its capacity building. It is a vital step that will help improve timely access to effective, quality therapies, and vaccines for all patients, in every corner of Africa.
“Africa is battling increased burden of infectious, neglected tropical, and non-communicable diseases and struggles against widespread availability of falsified medicines. By adopting such treaty, African health leaders show their determination to address the regulatory challenges they face and we as industry are ready to continue in our support to them.” Says Thomas Cueni, IFPMA Director General.
“IFPMA and namely our Africa Regulatory Working Group welcome the development of the AMA and look forward to the role it will play in fostering regulatory system strengthening and reliance across Africa towards faster and expanded access to effective, safe, and quality medicines for patients. We strongly support the holistic vision of ongoing harmonization activities and inclusion of regulatory activities spanning the life-cycle of medicines, vaccines, and biotherapeutics that will be reflected in the newly established agency.” Thomas Cueni added.
AMA is built upon and accelerates the current momentum of strengthening regulatory system in the continent. The African Union and the Africa Medicines Regulatory Harmonization (AMRH) initiative are striving to build a solid framework for the AMA on a regional economic community level.
People and patients in Africa are waiting for a clear signal that solutions for their healthcare are possible. AMA is one.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
How we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
Lessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more